Welcome to our dedicated page for Innospec SEC filings (Ticker: IOSP), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Innospec Inc. filings document the financial reporting, governance and capital-return disclosures of a specialty chemicals operating company. Form 8-K reports record quarterly and annual results, segment commentary for Performance Chemicals, Fuel Specialties and Oilfield Services, Regulation FD disclosures, semi-annual dividends and board-authorized common stock repurchase programs.
The company’s proxy materials describe annual meeting matters, director elections, executive compensation votes, auditor ratification and related governance procedures. Its filings also identify IOSP common stock as a NASDAQ-listed security and provide formal disclosure around results of operations, financial condition, risk-related business context and shareholder voting matters.
Innospec Inc. director Larry Padfield reported amended insider sales of company common stock. The Form 4/A corrects transaction prices previously reported. On February 27, 2026, he sold 287 shares at $76.30 and 307 shares at $76.79 in open-market transactions, totaling 594 shares.
The footnotes explain that each reported price is a weighted average. The 287-share sale occurred in multiple trades between $75.5001 and $76.55, and the 307-share sale in trades between $76.555 and $77.0713. After these transactions, his directly held ownership was reported as 9,453 shares of Innospec common stock.
Innospec Inc. director Claudia Poccia reported amended insider stock sales. The Form 4/A corrects transaction prices previously reported for two open-market sales of Innospec common stock on February 27, 2026.
The amended filing shows sales totaling 119 shares, with 57 shares sold at a weighted average price of $76.30 and 62 shares sold at a weighted average price of $76.79. After these transactions, Poccia directly owned 6,508 shares of Innospec common stock.
The footnotes explain that each reported price is a weighted average and that the shares were sold in multiple transactions, with individual prices ranging from $75.5001 to $76.55 for the first sale and from $76.555 to $77.0713 for the second sale. Poccia has undertaken to provide full trade details, including exact share amounts and prices for each execution, to the SEC staff, Innospec, or any Innospec security holder upon request.
Innospec Inc. director David Landless reported selling 594 shares of common stock in two open-market transactions. On February 27, 2026, he sold 287 shares at a weighted average price of $76.30 and 307 shares at a weighted average price of $76.79.
This amended Form 4 corrects the previously reported transaction prices and states that the prices reflect weighted averages. The first sale occurred in multiple trades between $75.5001 and $76.55, and the second between $76.555 and $77.0713. Following these sales, he directly holds 7,632 shares.
Innospec Inc. executive Ian Cleminson, EVP & CFO, reported amended insider stock sales. On February 27, 2026, he sold a total of 2,380 shares of Innospec common stock in two open-market transactions at weighted average prices of $76.30 and $76.79 per share. After these sales, he directly owned 20,357 shares of common stock. The amendment corrects previously reported transaction prices and notes the shares were sold in multiple trades within price ranges from $75.5001 to $76.55 and from $76.555 to $77.0713.
Innospec Inc. director Milton C. Blackmore reported an open-market sale of 594 shares of Innospec common stock. The transaction took place on February 27, 2026 at a price of $76.5562 per share. After this sale, he directly owns 10,530 shares of Innospec.
Innospec Inc. director Larry Padfield reported an open-market sale of common stock. He sold 594 shares at an average price of $76.5562 per share. After this transaction, he directly owns 9,453 shares of Innospec common stock.
Innospec Inc. director Claudia Poccia reported an open-market sale of 119 shares of common stock at an average price of $76.5562 per share. According to the filing, these shares were sold through a broker transaction solely to cover tax withholding obligations related to the vesting of time-based restricted stock units. After this tax-related sale, Poccia beneficially owns 6,508 Innospec common shares directly.
Innospec Inc. senior vice president of human resources Hardy Louis Griffin III reported a small insider transaction related to equity compensation. On vesting of a restricted stock unit award, 401 shares of common stock were automatically withheld at $78.34 per share to cover income tax obligations, rather than being an open‑market trade. After this tax-withholding disposition, Griffin directly owned 10,161 common shares, reflecting his remaining equity stake in the company.
Innospec Inc. director David Landless reported an open-market sale of 594 shares of Innospec common stock at an average price of $76.5562 per share on February 27, 2026. After this transaction, he directly holds 7,632 shares of the company’s common stock.
Innospec Inc. senior vice president, general counsel and chief compliance officer David B. Jones reported two stock transactions. He sold 1,028 shares of common stock in an open-market sale at $75.64 per share and had 875 shares withheld to cover taxes upon vesting of restricted stock units. After these transactions, he directly owned 14,693 shares of Innospec common stock.